학술논문

177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
Document Type
Article
Source
In: The Lancet Oncology. (The Lancet Oncology, December 2021, 22(12):1752-1763)
Subject
Language
English
ISSN
14745488
14702045